Jupiter Neurosciences, Inc. $JUNS Shares Sold by Vestor Capital LLC

Vestor Capital LLC lowered its stake in Jupiter Neurosciences, Inc. (NASDAQ:JUNS) by 98.6% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,009 shares of the company’s stock after selling 959,169 shares during the quarter. Vestor Capital LLC owned approximately 1.54% of Jupiter Neurosciences worth $34,000 as of its most recent filing with the SEC.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on JUNS. Weiss Ratings reissued a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Monday, September 21st. Wall Street Zen upgraded Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 16th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has a consensus rating of “Sell”.

Jupiter Neurosciences Stock Performance

JUNS stock opened at $2.22 on Wednesday. The business has a fifty day simple moving average of $2.79 and a 200-day simple moving average of $18.87. Jupiter Neurosciences, Inc. has a 52 week low of $2.01 and a 52 week high of $103.50.

Jupiter Neurosciences (NASDAQ:JUNS) last posted its quarterly earnings results on Friday, August 14th. The company reported ($5.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.75) by ($1.31). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.40 million.

Jupiter Neurosciences Profile

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) is a clinical-stage biotechnology company focused on developing therapies for diseases associated with neuroinflammation. The company’s research is centered on small-molecule drug candidates intended to address inflammatory processes affecting the central nervous system. Jupiter Neurosciences’ lead product candidate, JNS-101, is an orally administered, brain-penetrant compound being developed for its potential anti-inflammatory and neuroprotective effects.